This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Clozapine: Difference between revisions
>Corticosteroid Grammatics |
>Corticosteroid reword/citeflag/categories |
||
| Line 5: | Line 5: | ||
{{SubstanceBox/Clozapine}} | {{SubstanceBox/Clozapine}} | ||
'''Clozapine''' (trade names '''Clozaril''' and '''FazaClo''') is an atypical antipsychotic medication that is used to treat | '''Clozapine''' (trade names '''Clozaril''' and '''FazaClo''') is an atypical antipsychotic medication that is used to treat treatment-resistant schizophrenia. However, it only applies to those that have not responded to other medications (studies demonstrated that clozapine was more effective against treatment-resistant schizophrenia than other antipsychotics){{citation needed}}. Therefore, it is a drug of last resort (DoLR). | ||
Clozapine may also be used to help reduce the risk of suicidal tendencies in people with schizophrenia or other disorders that can be similar, such as acute delirium, bipolar disorder, and extreme cases of anxiety. However, its only ''approved'' (on-label) use is in treatment-resistant schizophrenia.<ref> Novartis Corporation, Prescribing Guide For Clozapine (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019758s062lbl.pdf)</ref> Clozapine was first synthesized in 1958 by Wander AG, a Swiss pharmaceutical company, based on the chemical structure of the tricyclic antidepressant imipramine. | Clozapine may also be used to help reduce the risk of suicidal tendencies in people with schizophrenia or other disorders that can be similar, such as acute delirium, bipolar disorder, and extreme cases of anxiety. However, its only ''approved'' (on-label) use is in treatment-resistant schizophrenia.<ref> Novartis Corporation, Prescribing Guide For Clozapine (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019758s062lbl.pdf)</ref> Clozapine was first synthesized in 1958 by Wander AG, a Swiss pharmaceutical company, based on the chemical structure of the tricyclic antidepressant imipramine. | ||
| Line 41: | Line 41: | ||
*'''[[Effect::Sleepiness]]''' | *'''[[Effect::Sleepiness]]''' | ||
*'''[[Effect::Delusions]]''' | *'''[[Effect::Delusions]]''' | ||
*'''[[Effect::Hallucinations]]''' | *'''[[Effect::Hallucinations]]''' | ||
*'''[[Effect::Amnesia]]''' | *'''[[Effect::Amnesia]]''' | ||
*'''[[Effect::Irritability]]''' | *'''[[Effect::Irritability]]''' | ||
*'''[[Effect::Confusion]]''' | *'''[[Effect::Confusion]]''' and '''[[Effect::Delirium|delirium]]''' | ||
*'''[[Effect::Cognitive fatigue]]''' | *'''[[Effect::Cognitive fatigue]]''' | ||
}} | }} | ||
| Line 80: | Line 80: | ||
==References== | ==References== | ||
format these fuckers correctly please. and where are the <ref> tags ele-mayo | |||
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/19758se1-047ltr.pdf | http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/19758se1-047ltr.pdf | ||
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0009695/?report=details#side_effects | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0009695/?report=details#side_effects | ||
https://www.ncbi.nlm.nih.gov/mesh/68003024 | https://www.ncbi.nlm.nih.gov/mesh/68003024 | ||
[[Category:Psychoactive substance]][[Category:Articles in talk page]][[Category:Proofread]][[Category:Approval]] | |||